Tempus AI Inc

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tempus AI Inc reports strong Q3 results and strategic acquisitions

Tempus AI Inc (TEM) showcased robust performance in Q3 2024, driven by revenue growth and strategic acquisitions, positioning the company for continued success.
While challenges like organizational readiness and market dynamics exist, the company's disciplined approach and strong partnerships present opportunities for sustained growth.
Overall, Tempus' focus on innovation, customer-centricity, and financial discipline sets a solid foundation for future growth and market leadership in the healthcare technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. TEM, a cutting-edge healthcare diagnostics company, has been on a tear. The stock established a new high of $47.81 on Thursday.

Tempus AI Soars To New Highs, Investments From Google And SoftBank Boost Bullish Sentiment

Personalis Inc

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the recent ASCO meeting. Tempus is serving as exclusive commercial partner for Personalis' ultra-sensitive tumor-informed MRD product for broad patient adoption in breast and lung cancers,.

Personalis and Tempus Announce Expanded Collaboration

Cronos Group

IAMGOLD

Li Auto Inc.

Marathon Digital Holdings

MINISO Group Holding

PACS Group, Inc.

The S&P 500 index touched highs of 5,670 in July. Over the last one month, the index movement has been volatile with a downward bias.

7 Growth Stocks to Buy on Corrections for 3X Returns by 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of its human leukocyte antigen (HLA) loss of heterozygosity (LOH) investigational assay has been published in npj Precision Oncology. Titled, “Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities,” the study included analytica.

NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay

DraftKings

EHang Holdings Ltd - ADR

First Solar

Ibotta Inc

The recent market correction is a reminder to investors that it's important to remain grounded even during bull markets. By this, I imply having a balanced portfolio and staying away from overvalued stocks.

7 Growth Stocks That Could 7X in the Next 7 Years

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended June 30, 2024, and provided recent business highlights. Revenue increased 25% year-over-year to $166.0 million in the second quarter of 2024 Data licensing revenue growth accelerated to 40% year-over-year Expanded into the minimal residual disease (MRD) market with the launch of both t.

Tempus Reports Second Quarter 2024 Results

Rapport Therapeutics Inc

Global markets are down as fears of an economic downturn triggered a near-term crisis. This is a reminder that corrections can come from most unexpected events.

3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns

Medtronic

Moderna

AI healthcare stocks can potentially revolutionize patient care as we know it. The groundbreaking technology is expected to have a pervasive impact on the investment world, with its most profound anticipated transformations in healthcare.

3 AI-Powered Healthcare Stocks Transforming Medicine

Loar Holdings Inc

Viking Holdings Ltd

ZEEKR Intelligent Technology Holding Ltd

The initial public offering (IPO) and the subsequent listing is one of the best times to buy new growth stocks. The markets are still in a phase of understanding the business potential and there is limited analyst coverage.

7 New Growth Stock Listings That Can Be Long-Term Wealth Creators

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable biomarkers, and who should receive confirmatory testing in accordance with clinical guidelines. This program is part of the larger Tempus Next platform, which is designed to identify care gaps and equip clinicians with ac.

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease. The collaboration between Remix and Tempus began with the licensing of specific, de-identified data cohorts and has since expanded into a broader, strategic alliance. Remix is.

Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics

Stryker

Across industries, companies will need to adopt AI for growth and survival. A PricewaterhouseCoopers indicates that by 2030, AI could contribute up to $15.7 trillion to the global economy.

3 AI-in-Healthcare Stocks to Buy for Outsized Returns

Archer Aviation

Leonardo DRS Inc

MakeMyTrip

In June 2010, Tesla (NASDAQ: TSLA ) was listed with a market valuation of $2.23 billion. Currently, the EV maker commands a market valuation of $785 billion.

7 Growth Stocks That Can Create Millionaires by 2030

Before entering the markets, investors need to clearly define their objective. If the idea is to take low-risk and beat inflation, it makes sense to go overweight on blue-chip stocks trading at attractive valuations.

7 Millionaire-Making Growth Stocks to Buy and Forget

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast wi.

Tempus to Report Second Quarter 2024 Financial Results on August 6

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio being developed at Tempus to bring next-generation algorithmic diagnostics to the immuno-oncology space. Additionally, Tempus is collaborating with other partners, like Cleveland Clinic, t.

Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests

HealthStream

BOSTON--(BUSINESS WIRE)-- #EmployeeEngagement--Lifeline Ambulance has successfully reduced operational costs by $460,000 and attrition by 58% by using Blink's employee engagement platform.

Lifeline Ambulance Saves $460,000 and Cuts Attrition by 58% with Blink's Employee Engagement Super-App

With the S&P 500 index trading near all-time highs, the initial public offering market has been robust. It's also not uncommon that quality IPO stocks remain under-the-radar for a while before surging higher as it catches analyst and investor attention.

3 Under-the-Radar IPO Stocks to Buy Before They Double

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research supported by the company's multimodal data library. This research milestone includes published and/or acknowledged wor.

Tempus Surpasses 500 Research Publications

William Blair initiated coverage on Tempus AI, Inc TEM, citing the company's ‘differentiated approach and business model.'

Tempus AI Has Massive Market Opportunity For This Healthcare Technology, Bullish Analyst Says

Several analysts kicked off coverage of Tempus AI (TEM) with bullish comments, anticipating gains from the biotech company's applications of artificial intelligence (AI) to healthcare.

Why Wall Street Is Bullish on Healthcare Tech Stock Tempus AI

Tempus AI (NASDAQ:TEM), a provider of AI-enabled precision medicine, has been initiated with a 'buy' rating by Bank of America, which likes how the company combines a patient's molecular, clinical and other data to provide a new level of medical diagnostics.  There are other companies that provide similar molecular diagnostics – Guardant Health, Foundation Medicine, NeoGenomics (NASDAQ:NEO) for three – Tempus differs from most of them by adding layers of additional patient information such as MRI imaging data, patient records, as well as AI techniques such as neural networks, deep learning, and large language models.

AI-boosted medical diagnostics firm Tempus AI given 'buy' rating

A number of Wall Street analysts on Tuesday made bullish calls on the shares of a newly public healthcare company that uses artificial intelligence to differentiate itself in the cancer-diagnostics space.

Buy this healthcare company's stock because it's an AI play, analysts say

Wall Street brokerages started covering SoftBank Group-backed Tempus AI on a bullish note on Tuesday, betting that the company's AI-powered library of clinical and molecular data could lead to more powerful diagnostic and test kits.

Wall Street analysts bullish on genetic testing firm Tempus AI

TIMBERLAKE, N.C.--(BUSINESS WIRE)--The Call for Content for IASA's Xchange annual conference held June 8–10, 2025, in St. Louis, is now open.

News for Tempus AI Inc Stock (TEM)